245 research outputs found
Multinational study exploring patients' perceptions of side-effects induced by chemo-radiotherapy
No full textPurpose: We aimed to prospectively assess the incidence, severity and patients' perceptions of side-effects induced by radiotherapy and concomitant weekly cisplatin. Patients and Methods: This multinational survey included patients with a diagnosis of gynaecological or head and neck cancer scheduled to receive radiotherapy and concomitant weekly cisplatin. Patients completed a questionnaire prior to anti-cancer treatment and after 3 weeks of treatment. Baseline frequency and severity of symptoms were compared to frequency and severity after 3 weeks of treatment, and patients were asked to rank the five most severe symptoms experienced. Results: An increase in the severity as well as in the mean number of symptoms (18 compared to 24) was observed during treatment. Patients ranked 7 of the 10 most feared baseline symptoms as non-physical, whereas 8 of the 10 most feared symptoms after 3 weeks of treatment were physical. Nausea was ranked as the 5th most severe symptom during treatment, despite 98% of patients receiving antiemetic prophylaxis. Conclusion: Patients with head and neck cancer or gynaecological cancer suffer from a number of primarily non-physical symptoms before starting combined chemo-radiotherapy. After 3 weeks of treatment patients score 8 of the 10 most feared symptoms as physical. Future trials focusing on the prevention of side-effects in patients receiving radiotherapy and concomitant chemotherapy are highly warranted.Christina H. Ruhlmann, Trine Zeeberg Iversen, Meena Okera, Aida Muhic, Gunnar Kristensen, Petra Feyer, Olfred Hansen, Jørn Herrsted
<strong>Cardiac Toxicity after definitive Radiotherapy of locally advanced NSCLC</strong>
No full textCardiac Toxicity after definitive Radiotherapy of locally advanced NSCLC Tine Schytte, Olfred Hansen, Thomine Stolberg-Rohr* and Carsten Brink*. Dept. Oncology and Radiophysic Lab.* Odense University Hospital, Denmark Keyword: Radiotherapy, Locally advanced NSCLC, Cardiac toxicity Background: Lung and oesophageal toxicity have been regarded as main toxicity in definitive radiotherapy (RT) of non-small cell lung cancer (NSCLC), whereas cardiac toxicity has not been offered much concern. This is probably due to the poor prognosis for patients with unresectable NSCLC. In this study we report the heart toxicities in locally-regionally advanced NSCLC (LA-NSCLC) patients (pts) treated with RT in our centre. Methods and material: From 01.01.1995-30.11.2007, 287 pts with LA-NSCLC (stage IIB-IIIB) were treated with RT at our centre with planned dose 60-66 Gy. All RT was applied as 3D RT in 2 Gy/F without elective nodal irradiation. Cardiac toxicity is defined as myocardial infarction (MI), exudative pericarditis (ED), cardiac insufficiency (CI), pulmonary embolism (PE), found dead with unknown cause, non specific cardiac disease (CD), supra- or ventricular arrhythmia (SA, VA). The cardiac events (CE) were collected from patient files. All patients were followed to death. Median follow-up was 86 month, with 24 month as minimum. Results: 38 pts had a CE: 7 MI, 3 EP, 5 CI, 4 PE, 2 found dead, 3 CD, 13 SA and 1 VA. Median survival was 17.2 month and overall survival for 1, 2 and 5 year was 64%, 35% and 14%, respectively. In a Cox regression analyses of time to CE, age > 65 year, + induction chemotherapy, smoking, high mean dose to left + right ventricles or whole heart was not a statistically significant factor, whereas low FEV-1, large GTV, low Hb, poor PS, high V20 to lunge, and gender did. Discussion: We did not find a correlation between high mean dose to left + right ventricles or whole heart and having a CE. Having a CE was not related to worsen survival. Factors in modelRelative Hazard Ratio(95% CI)p-valueFEV-1 (<75%)1.30 ( 1.00-1.68)0.046GTV (>150 ml)2.02 (1.51-2.71)<0.0001Hb (<12g/dL)1.44 (1.12-1.86)0.0046Mean dose to ventricles(>20 Gy)1.23 (0.92-1.67)0.17PS (>1)1.64 (1.11-2.42)0.014Gender (male)1.37 (1.06-1.77)0.016V20 (>35%)1.85 (1.43-2.40)<0.0001 Cardiac Toxicity after definitive Radiotherapy of locally advanced NSCLCTine Schytte, Olfred Hansen, Thomine Stolberg-Rohr* and Carsten Brink*. Dept. Oncology and Radiophysic Lab.* Odense University Hospital, Denmark Keyword: Radiotherapy, Locally advanced NSCLC, Cardiac toxicity Background: Lung and oesophageal toxicity have been regarded as main toxicity in definitive radiotherapy (RT) of non-small cell lung cancer (NSCLC), whereas cardiac toxicity has not been offered much concern. This is probably due to the poor prognosis for patients with unresectable NSCLC. In this study we report the heart toxicities in locally-regionally advanced NSCLC (LA-NSCLC) patients (pts) treated with RT in our centre. Methods and material:From 01.01.1995-30.11.2007, 287 pts with LA-NSCLC (stage IIB-IIIB) were treated with RT at our centre with planned dose 60-66 Gy. All RT was applied as 3D RT in 2 Gy/F without elective nodal irradiation. Cardiac toxicity is defined as myocardial infarction (MI), exudative pericarditis (ED), cardiac insufficiency (CI), pulmonary embolism (PE), found dead with unknown cause, non specific cardiac disease (CD), supra- or ventricular arrhythmia (SA, VA). The cardiac events (CE) were collected from patient files. All patients were followed to death. Median follow-up was 86 month, with 24 month as minimum. Results: 38 pts had a CE: 7 MI, 3 EP, 5 CI, 4 PE, 2 found dead, 3 CD, 13 SA and 1 VA. Median survival was 17.2 month and overall survival for 1, 2 and 5 year was 64%, 35% and 14%, respectively. In a Cox regression analyses of time to CE, age > 65 year, + induction chemotherapy, smoking, high mean dose to left + right ventricles or whole heart was not a statistically significant factor, whereas low FEV-1, large GTV, low Hb, poor PS, high V20 to lunge, and gender did. Discussion:We did not find a correlation between high mean dose to left + right ventricles or whole heart and having a CE. Having a CE was not related to worsen survival. Factors in modelRelative Hazard Ratio(95% CI)p-value FEV-1 (<75%)1.30 ( 1.00-1.68)0.046GTV (>150 ml)2.02 (1.51-2.71)<0.0001Hb (<12g/dL)1.44 (1.12-1.86)0.0046Mean dose to ventricles(>20 Gy)1.23 (0.92-1.67)0.17PS (>1)1.64 (1.11-2.42)0.014Gender (male)1.37 (1.06-1.77)0.016V20 (>35%)1.85 (1.43-2.40)<0.0001</p
<strong>Cardiac Toxicity after definitive Radiotherapy of locally advanced NSCLC</strong>
No full textCardiac Toxicity after definitive Radiotherapy of locally advanced NSCLC Tine Schytte, Olfred Hansen, Thomine Stolberg-Rohr* and Carsten Brink*. Dept. Oncology and Radiophysic Lab.* Odense University Hospital, Denmark Keyword: Radiotherapy, Locally advanced NSCLC, Cardiac toxicity Background: Lung and oesophageal toxicity have been regarded as main toxicity in definitive radiotherapy (RT) of non-small cell lung cancer (NSCLC), whereas cardiac toxicity has not been offered much concern. This is probably due to the poor prognosis for patients with unresectable NSCLC. In this study we report the heart toxicities in locally-regionally advanced NSCLC (LA-NSCLC) patients (pts) treated with RT in our centre. Methods and material: From 01.01.1995-30.11.2007, 287 pts with LA-NSCLC (stage IIB-IIIB) were treated with RT at our centre with planned dose 60-66 Gy. All RT was applied as 3D RT in 2 Gy/F without elective nodal irradiation. Cardiac toxicity is defined as myocardial infarction (MI), exudative pericarditis (ED), cardiac insufficiency (CI), pulmonary embolism (PE), found dead with unknown cause, non specific cardiac disease (CD), supra- or ventricular arrhythmia (SA, VA). The cardiac events (CE) were collected from patient files. All patients were followed to death. Median follow-up was 86 month, with 24 month as minimum. Results: 38 pts had a CE: 7 MI, 3 EP, 5 CI, 4 PE, 2 found dead, 3 CD, 13 SA and 1 VA. Median survival was 17.2 month and overall survival for 1, 2 and 5 year was 64%, 35% and 14%, respectively. In a Cox regression analyses of time to CE, age > 65 year, + induction chemotherapy, smoking, high mean dose to left + right ventricles or whole heart was not a statistically significant factor, whereas low FEV-1, large GTV, low Hb, poor PS, high V20 to lunge, and gender did. Discussion: We did not find a correlation between high mean dose to left + right ventricles or whole heart and having a CE. Having a CE was not related to worsen survival. Factors in modelRelative Hazard Ratio(95% CI)p-valueFEV-1 (<75%)1.30 ( 1.00-1.68)0.046GTV (>150 ml)2.02 (1.51-2.71)<0.0001Hb (<12g/dL)1.44 (1.12-1.86)0.0046Mean dose to ventricles(>20 Gy)1.23 (0.92-1.67)0.17PS (>1)1.64 (1.11-2.42)0.014Gender (male)1.37 (1.06-1.77)0.016V20 (>35%)1.85 (1.43-2.40)<0.0001 Cardiac Toxicity after definitive Radiotherapy of locally advanced NSCLCTine Schytte, Olfred Hansen, Thomine Stolberg-Rohr* and Carsten Brink*. Dept. Oncology and Radiophysic Lab.* Odense University Hospital, Denmark Keyword: Radiotherapy, Locally advanced NSCLC, Cardiac toxicity Background: Lung and oesophageal toxicity have been regarded as main toxicity in definitive radiotherapy (RT) of non-small cell lung cancer (NSCLC), whereas cardiac toxicity has not been offered much concern. This is probably due to the poor prognosis for patients with unresectable NSCLC. In this study we report the heart toxicities in locally-regionally advanced NSCLC (LA-NSCLC) patients (pts) treated with RT in our centre. Methods and material:From 01.01.1995-30.11.2007, 287 pts with LA-NSCLC (stage IIB-IIIB) were treated with RT at our centre with planned dose 60-66 Gy. All RT was applied as 3D RT in 2 Gy/F without elective nodal irradiation. Cardiac toxicity is defined as myocardial infarction (MI), exudative pericarditis (ED), cardiac insufficiency (CI), pulmonary embolism (PE), found dead with unknown cause, non specific cardiac disease (CD), supra- or ventricular arrhythmia (SA, VA). The cardiac events (CE) were collected from patient files. All patients were followed to death. Median follow-up was 86 month, with 24 month as minimum. Results: 38 pts had a CE: 7 MI, 3 EP, 5 CI, 4 PE, 2 found dead, 3 CD, 13 SA and 1 VA. Median survival was 17.2 month and overall survival for 1, 2 and 5 year was 64%, 35% and 14%, respectively. In a Cox regression analyses of time to CE, age > 65 year, + induction chemotherapy, smoking, high mean dose to left + right ventricles or whole heart was not a statistically significant factor, whereas low FEV-1, large GTV, low Hb, poor PS, high V20 to lunge, and gender did. Discussion:We did not find a correlation between high mean dose to left + right ventricles or whole heart and having a CE. Having a CE was not related to worsen survival. Factors in modelRelative Hazard Ratio(95% CI)p-value FEV-1 (<75%)1.30 ( 1.00-1.68)0.046GTV (>150 ml)2.02 (1.51-2.71)<0.0001Hb (<12g/dL)1.44 (1.12-1.86)0.0046Mean dose to ventricles(>20 Gy)1.23 (0.92-1.67)0.17PS (>1)1.64 (1.11-2.42)0.014Gender (male)1.37 (1.06-1.77)0.016V20 (>35%)1.85 (1.43-2.40)<0.0001</p
The occurrence of hyponatremia in SCLC and the influence on prognosis: a retrospective study of 453 patients treated in a single institution in a 10-year period
No full textHyponatremia is often seen in SCLC, and is thought to be caused by the paraneoplastic syndrome SIADH. Variable results of the prognostic significance of low P-sodium (P-Na) have been reported. This study was performed to investigate the prognostic value of hyponatremia in SCLC. Data was obtained from files from 453 patients diagnosed with SCLC and treated at Odense University Hospital from 1995 to 2005 in which data on P-sodium was available. The standard chemotherapy was six cycles of carboplatin-etoposide. P-Na wa
P2-306: Epoetin beta (EPO) together with Carboplatin/Gemcitabine (CaGem) chemotherapy for advanced NSCLC: A phase II study with matched controls
No full textEmbracing Life after Prostate Cancer. A male perspective of treatment and rehabilitation
No full text- …
